Mumbai, December 27, 2016: Pharma Major Lupin Limited (Lupin) announced today that it has launched its Voriconazole Tablets, 50 mg & 200 mg and Voriconazole Oral Suspension, 40 mg/mL having received an approval from the United States Food and Drug Administration (FDA) earlier to market a generic equivalent of PF Prism C.V’s Vfend® Tablets, 50 mg & 200 mg and Vfend® Oral Suspension, 40 mg/mL.
Voriconazole Tablets, 50 mg & 200 mg and Voriconazole Oral Suspension, 40 mg/mL are the AB rated generic equivalent of PF Prism C.V’s Vfend® Tablets, 50 mg & 200 mg and Vfend® Oral Suspension, 40 mg/mL. It is indicated for use in patients 12 years of age and older in the treatment of the following fungal infections:
1. Invasive Aspergillosis
2. Candidemia in Non-neutropenic patients and the following Candida infections: Disseminated infections in skin and infections in abdomen, kidney, bladder wall and wounds
3. Esophageal Candidiasis
4. Serious fungal infections caused by Scedosporium apiospermum (Asexual form of Pseudallescheria boydii) and Fusarium spp. including Fusarium solani in patients intolerant of or refractory to other therapy
Vfend® Tablets, 50mg & 200mg had US sales of USD 81 million (IMS MAT September 2016) while Vfend® Oral Suspension, 40 mg/mL had US sales of USD 15.2 million (IMS MAT September 2016).
Corporate Comm India(CCI Newswire)
